238 related articles for article (PubMed ID: 25205143)
1. Incretin-based drugs and the risk of congestive heart failure.
Yu OH; Filion KB; Azoulay L; Patenaude V; Majdan A; Suissa S
Diabetes Care; 2015 Feb; 38(2):277-84. PubMed ID: 25205143
[TBL] [Abstract][Full Text] [Related]
2. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study.
Azoulay L; Filion KB; Platt RW; Dahl M; Dormuth CR; Clemens KK; Durand M; Juurlink DN; Targownik LE; Turin TC; Paterson JM; Ernst P;
BMJ; 2016 Feb; 352():i581. PubMed ID: 26888382
[TBL] [Abstract][Full Text] [Related]
3. Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis.
Azoulay L; Filion KB; Platt RW; Dahl M; Dormuth CR; Clemens KK; Durand M; Hu N; Juurlink DN; Paterson JM; Targownik LE; Turin TC; Ernst P; ; Suissa S; Dormuth CR; Hemmelgarn BR; Teare GF; Caetano P; Chateau D; Henry DA; Paterson JM; LeLorier J; Levy AR; Ernst P; Platt RW; Sketris IS
JAMA Intern Med; 2016 Oct; 176(10):1464-1473. PubMed ID: 27479930
[TBL] [Abstract][Full Text] [Related]
4. A Multicenter Observational Study of Incretin-based Drugs and Heart Failure.
Filion KB; Azoulay L; Platt RW; Dahl M; Dormuth CR; Clemens KK; Hu N; Paterson JM; Targownik L; Turin TC; Udell JA; Ernst P;
N Engl J Med; 2016 Mar; 374(12):1145-54. PubMed ID: 27007958
[TBL] [Abstract][Full Text] [Related]
5. Incretin-based Drugs and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes.
Abrahami D; Yin H; Yu OHY; Pollak MN; Azoulay L
Epidemiology; 2018 Mar; 29(2):246-253. PubMed ID: 29283894
[TBL] [Abstract][Full Text] [Related]
6. Incretin-based therapy and risk of acute pancreatitis: a nationwide population-based case-control study.
Thomsen RW; Pedersen L; Møller N; Kahlert J; Beck-Nielsen H; Sørensen HT
Diabetes Care; 2015 Jun; 38(6):1089-98. PubMed ID: 25633664
[TBL] [Abstract][Full Text] [Related]
7. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study.
Abrahami D; Douros A; Yin H; Yu OH; Faillie JL; Montastruc F; Platt RW; Bouganim N; Azoulay L
BMJ; 2018 Dec; 363():k4880. PubMed ID: 30518618
[TBL] [Abstract][Full Text] [Related]
8. Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus.
Faillie JL; Yu OH; Yin H; Hillaire-Buys D; Barkun A; Azoulay L
JAMA Intern Med; 2016 Oct; 176(10):1474-1481. PubMed ID: 27478902
[TBL] [Abstract][Full Text] [Related]
9. Use of incretin agents and risk of pancreatic cancer: a population-based cohort study.
Knapen LM; van Dalem J; Keulemans YC; van Erp NP; Bazelier MT; De Bruin ML; Leufkens HG; Croes S; Neef C; de Vries F; Driessen JH
Diabetes Obes Metab; 2016 Mar; 18(3):258-65. PubMed ID: 26537555
[TBL] [Abstract][Full Text] [Related]
10. Antidiabetic therapy and the risk of heart failure in type 2 diabetic patients: an independent effect or confounding by indication.
Koro CE; Bowlin SJ; Weiss SR
Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):697-703. PubMed ID: 15654719
[TBL] [Abstract][Full Text] [Related]
11. Incretin-based drugs and hospitalization for heart failure in the clinical practice: A nested case-control study.
Santucci C; Franchi M; Staszewsky L; La Vecchia C; Latini R; Merlino L; Corrao G; Bosetti C
Diabetes Res Clin Pract; 2018 Dec; 146():172-179. PubMed ID: 30332619
[TBL] [Abstract][Full Text] [Related]
12. Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the Cleveland Clinic.
Kannan S; Pantalone KM; Matsuda S; Wells BJ; Karafa M; Zimmerman RS
J Diabetes; 2016 Mar; 8(2):279-85. PubMed ID: 25929426
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl peptidase-4 inhibitors and the risk of community-acquired pneumonia in patients with type 2 diabetes.
Faillie JL; Filion KB; Patenaude V; Ernst P; Azoulay L
Diabetes Obes Metab; 2015 Apr; 17(4):379-85. PubMed ID: 25581902
[TBL] [Abstract][Full Text] [Related]
14. Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study.
Knapen LM; de Jong RG; Driessen JH; Keulemans YC; van Erp NP; De Bruin ML; Leufkens HG; Croes S; de Vries F
Diabetes Obes Metab; 2017 Mar; 19(3):401-411. PubMed ID: 27883260
[TBL] [Abstract][Full Text] [Related]
15. Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study.
Faillie JL; Azoulay L; Patenaude V; Hillaire-Buys D; Suissa S
BMJ; 2014 Apr; 348():g2780. PubMed ID: 24764569
[TBL] [Abstract][Full Text] [Related]
16. The safety of incretin based drug treatments for type 2 diabetes.
Bolen SD; Maruthur NM
BMJ; 2016 Feb; 352():i801. PubMed ID: 26888024
[No Abstract] [Full Text] [Related]
17. Welcome reassurance about GLP-1 drugs--but they are still young and not fully grown.
Riddle MC
Diabetes Care; 2015 Feb; 38(2):183-5. PubMed ID: 25614687
[No Abstract] [Full Text] [Related]
18. The safety of incretin based drugs.
Montori VM
BMJ; 2014 Apr; 348():g2779. PubMed ID: 24764568
[No Abstract] [Full Text] [Related]
19. Risk of new-onset heart failure in patients using sitagliptin: a population-based cohort study.
Eurich DT; Weir DL; Simpson SH; Senthilselvan A; McAlister FA
Diabet Med; 2016 May; 33(5):621-30. PubMed ID: 26206341
[TBL] [Abstract][Full Text] [Related]
20. Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database.
Faillie JL; Babai S; Crépin S; Bres V; Laroche ML; Le Louet H; Petit P; Montastruc JL; Hillaire-Buys D;
Acta Diabetol; 2014; 51(3):491-7. PubMed ID: 24352344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
